Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.55 |
| ▸ | GAA | P10253 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 5/20 | 0.48 |
| ▸ | MEN1 | O00255 | 4/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | BRD4 | O60885 | 1/20 | 0.48 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | MB | P02144 | 1/20 | 0.48 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.48 |
| ▸ | CA3 | P07451 | 1/20 | 0.48 |
| ▸ | RARG | P13631 | 1/20 | 0.48 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.48 |
| ▸ | CA4 | P22748 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18751502 | 0.88 | LMNA (0.52) | LMNAALDH1A1TDP1GAAMAPT | |
| SCHEMBL21487494 | 0.87 | LMNA (0.50) | LMNAALDH1A1TDP1GAAMAPT | |
| SCHEMBL26467103 | 0.87 | LMNA (0.50) | LMNAALDH1A1TDP1GAAMAPT | |
| SCHEMBL21487311 | 0.81 | HTT (0.52) | LMNAALDH1A1TDP1GAAMAPT | |
| SCHEMBL11136694 | 0.81 | LMNA (0.52) | LMNAALDH1A1TDP1GAAMAPT | |
| SCHEMBL3071609 | 0.78 | LMNA (0.71) | LMNAALDH1A1TDP1GAAMAPT | |
| SCHEMBL693623 | 0.78 | PKM (0.54) | LMNAALDH1A1TDP1GAAMAPT | |
| SCHEMBL24728205 | 0.77 | LMNA (0.64) | LMNAALDH1A1TDP1GAAMAPT | |
| SCHEMBL22864579 | 0.77 | LMNA (0.58) | LMNAALDH1A1TDP1GAAMAPT | |
| SCHEMBL7659979 | 0.77 | HTT (0.54) | ALDH1A1TDP1MAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170050937-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | MYRIAD GENETICS, INC. | 2017-02-23 | — | — | US | disclosed |
| US-20130029942-A1 | COMPOUNDS AND THERAPEUTICAL USES THEREOF | MYREXIS, INC. (US) | 2013-01-31 | — | — | US | disclosed |
| US-8309562-B2 | Compounds and therapeutical use thereof | MYREXIS, INC. (US) | 2012-11-13 | — | — | US | disclosed |
| US-20100069383-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | Myriad Pharmaceuticals, Incorporated (US) | 2010-03-18 | — | — | US | disclosed |
| US-7618975-B2 | 4-arylamino-quinazolines and analogs as activators of caspases and inducers of apoptosis and the use thereof | MYRIAD PHARMACEUTICALS, INC. (US) | 2009-11-17 | — | — | US | disclosed |
| US-20080039479-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | MYRIAD GENETICS, INCORPORATED (US) | 2008-02-14 | — | — | US | disclosed |
| US-20080032974-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | MYRIAD GENETICS, INCORPORATED (US) | 2008-02-07 | — | — | US | disclosed |
| US-20070249601-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | MYRIAD GENETICS, INCORPORATED (US) | 2007-10-25 | — | — | US | disclosed |
| US-20070244114-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | MYRIAD GENETICS, INCORPORATED (US) | 2007-10-18 | — | — | US | disclosed |
| US-20070244113-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | MYRIAD GENETICS, INCORPORATED (US) | 2007-10-18 | — | — | US | disclosed |
| US-5736335-A | Dry elements, test devices, test kits and methods for chemiluminescent detection of analytes using peroxidase-labeled reagents | EASTMAN KODAK COMPANY (US) | 1998-04-07 | — | — | US | disclosed |
| US-5705357-A | DETECTING PEROXIDASE; SENSITIVITY, LOW BACKGROUND; MEDICAL DIAGNOSIS | JOHNSON & JOHNSON CLINICAL DIAGNOSTICS, INC. (US) | 1998-01-06 | — | — | US | disclosed |
| US-5641635-A | Dry elements, test devices, test kits and methods for chemiluminescent detection of analytes using peroxidase-labeled reagents | EASTMAN KODAK COMPANY (US) | 1997-06-24 | — | — | US | disclosed |
| EP-0704539-A2 | Chemiluminescent reagent and assay using a substituted acetanilide for light generation | JOHNSON & JOHNSON CLINICAL DIAGNOSTICS, INC. (US) | 1996-04-03 | — | — | EP | disclosed |
| US-5372931-A | Use of 4'-hydroxy- and 4'-alkoxy-substituted electron transfer agents in compositions, elements, test kits and analytical methods | EASTMAN KODAK COMPANY (US) | 1994-12-13 | — | — | US | disclosed |
| US-5372932-A | Peroxidase-labeled immunoreactant; stabiliztion with a 4-hydroxy or 4-alkoxyarylacetamide | EASTMAN KODAK COMPANY (US) | 1994-12-13 | — | — | US | disclosed |
| EP-0603953-A1 | Use of 4' of 5'-hydroxy and 4'- or 5'-alkoxy-substituted electron transfer agents in compositions, elements, test kits and analytical methods | Johnson & Johnson Clinical Diagnostics, Inc. (US) | 1994-06-29 | — | — | EP | disclosed |
| EP-0603954-A2 | Analytical element and immunoassay using a 4-hydroxy or 4-alkoxyarylacetamide as stabilizer | Johnson & Johnson Clinical Diagnostics, Inc. (US) | 1994-06-29 | — | — | EP | disclosed |
| EP-0589018-A1 | AMINES AS INHIBITORS OF SQUALENE SYNTHASE | ZENECA LIMITED (GB) | 1994-03-30 | — | — | EP | disclosed |
| WO-1993020807-A1 | AMINES AS INHIBITORS OF SQUALENE SYNTHASE | ZENECA LIMITED (GB) | 1993-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130029942-A1 | COMPOUNDS AND THERAPEUTICAL USES THEREOF | BAD, CASP3, BAX | LMNA 940/4885ALDH1A1 1143/4885TDP1 1329/4885 |
| US-20100069383-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | BAD, CASP3, BAX | LMNA 1005/4885ALDH1A1 1131/4885TDP1 1219/4885 |
| US-20070244113-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | BAD, CASP3, BAX | LMNA 1197/4885ALDH1A1 1179/4885TDP1 1061/4885 |
| US-20080032974-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | BAD, CASP3, BAX | LMNA 1197/4885ALDH1A1 1179/4885TDP1 1061/4885 |
| US-20170050937-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | BAD, CASP3, BAX | LMNA 1197/4885ALDH1A1 1179/4885TDP1 1061/4885 |
| US-20070244114-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | BAD, CASP3, BAX | LMNA 1197/4885ALDH1A1 1179/4885TDP1 1061/4885 |
| US-20080039479-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | BAD, CASP3, BAX | LMNA 1197/4885ALDH1A1 1179/4885TDP1 1061/4885 |
| US-20070249601-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | BAD, CASP3, BAX | LMNA 1197/4885ALDH1A1 1179/4885TDP1 1061/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.